{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:48:35Z","timestamp":1792259315085,"version":"4.4.0"},"reference-count":78,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: The treatment options for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have increased recently. However, drug resistance persists and patients who are ineligible for curative treatments still have a very poor prognosis. Previous studies support a general anti-neoplastic effect of metformin, and a recent preclinical investigation has shown that metformin may control the expansion of Dnmt3a clonal hematopoiesis, which is known to precede MDS and AML. \nPatients\/material and methods: In this study we investigated the effect of metformin and type 2 diabetes (T2D) on the risk of developing MDS or AML. T2D was defined based on hospital diagnosis codes and glucose-lowering drug prescriptions. The study was performed as a cohort study with follow-up from 1 January 2000 to 31 December 2017 using Danish national, population-based register data. \nResults and interpretation: In all, 6,031,132 persons contributed to the study of whom 302,403 had T2D, and 295,365 received metformin. Median follow-up time among individuals with T2D was more than 5 years, and among individuals without T2D more than 15 years. Our analyses revealed no association between T2D (hazard ratio [HR] 1.02 [95% confidence intervals (CI) 0.92\u20131.13]) or metformin use (HR 1.21 [95% CI 0.91\u20131.60]) and the risk of MDS or AML. However, when outcomes were studied separately, T2D was associated with an increased risk of MDS (HR 1.24 [95% CI 1.08\u20131.32]) but not with AML. Metformin use was not associated with MDS nor AML. Future studies should determine which patient groups may benefit from metformin to prevent MDS or AML development. <\/jats:p>","DOI":"10.2340\/1651-226x.2025.42422","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:28:09Z","timestamp":1746667689000},"page":"623-629","source":"Crossref","is-referenced-by-count":3,"title":["The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status \u2013 a Danish nation-wide cohort study"],"prefix":"10.2340","volume":"64","author":[{"given":"Emelie C.","family":"Rotbain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Rostgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Kaastrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Ulrik","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"109930","doi-asserted-by":"crossref","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"109931","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.blre.2019.04.005","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"109932","doi-asserted-by":"crossref","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","DOI":"10.1056\/NEJMoa1409405"},{"key":"109933","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1409405","DOI":"10.1056\/NEJMoa1409405"},{"key":"109934","doi-asserted-by":"crossref","unstructured":"Malcovati L, Gall\u00ec A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371\u20138.","DOI":"10.1182\/blood-2017-01-763425"},{"key":"109935","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2017-01-763425","DOI":"10.1182\/blood-2017-01-763425"},{"key":"109936","doi-asserted-by":"crossref","unstructured":"Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, et al. Metformin reduces the clonal fitness of Dnmt3aR878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state. Nature. 2024. Epub ahead of print.","DOI":"10.1038\/s41586-025-08871-w"},{"key":"109937","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41586-025-08871-w","DOI":"10.1038\/s41586-025-08871-w"},{"key":"109938","doi-asserted-by":"crossref","unstructured":"Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953\u201366.","DOI":"10.1016\/j.cmet.2014.09.018"},{"key":"109939","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cmet.2014.09.018","DOI":"10.1016\/j.cmet.2014.09.018"},{"key":"109940","doi-asserted-by":"crossref","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19:460\u201376.","DOI":"10.1038\/s41574-023-00833-4"},{"key":"109941","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41574-023-00833-4","DOI":"10.1038\/s41574-023-00833-4"},{"key":"109942","doi-asserted-by":"crossref","unstructured":"Glenth\u00f8j A, \u00d8rskov A, Hansen J, Hadrup S, O\u2019Connell C, Gr\u00f8nb\u00e6k K. Immune mechanisms in myelodysplastic syndrome. Int J Mol Sci. 2016;17:944.","DOI":"10.3390\/ijms17060944"},{"key":"109943","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms17060944","DOI":"10.3390\/ijms17060944"},{"key":"109944","doi-asserted-by":"crossref","unstructured":"Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304\u20135.","DOI":"10.1136\/bmj.38415.708634.F7"},{"key":"109945","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.38415.708634.F7","DOI":"10.1136\/bmj.38415.708634.F7"},{"key":"109946","doi-asserted-by":"crossref","unstructured":"Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014;7:867\u201385.","DOI":"10.1158\/1940-6207.CAPR-13-0424"},{"key":"109947","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0424","DOI":"10.1158\/1940-6207.CAPR-13-0424"},{"key":"109948","doi-asserted-by":"crossref","unstructured":"Wang Z, Phillips LS, Rohan TE, Ho GYF, Shadyab AH, Bidulescu A, et al. Diabetes, metformin use and risk of non-Hodgkin\u2019s lymphoma in postmenopausal women: a prospective cohort analysis in the Women\u2019s Health Initiative. Int J Cancer. 2023;152:1556\u201369.","DOI":"10.1002\/ijc.34376"},{"key":"109949","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ijc.34376","DOI":"10.1002\/ijc.34376"},{"key":"109950","doi-asserted-by":"crossref","unstructured":"Tseng CH. The risk of multiple myeloma is reduced in metformin initiators: a retrospective cohort study in Taiwanese patients with type 2 diabetes mellitus. Cancers (Basel). 2022;14(22):5637.","DOI":"10.3390\/cancers14225637"},{"key":"109951","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers14225637","DOI":"10.3390\/cancers14225637"},{"key":"109952","doi-asserted-by":"crossref","unstructured":"Tseng CH. Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes. Diabetes Metab. 2019;45:458\u201364.","DOI":"10.1016\/j.diabet.2019.05.002"},{"key":"109953","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.diabet.2019.05.002","DOI":"10.1016\/j.diabet.2019.05.002"},{"key":"109954","doi-asserted-by":"crossref","unstructured":"Kristensen DT, \u00d8vlisen AK, Jakobsen LHK, Severinsen MT, Hannig LH, Starklint J, et al. Metformin use and risk of myeloproliferative neoplasms: a Danish population\u2013based case-control study. Blood Adv. 2024;8:4478\u201385.","DOI":"10.1182\/bloodadvances.2023012266"},{"key":"109955","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012266","DOI":"10.1182\/bloodadvances.2023012266"},{"key":"109956","doi-asserted-by":"crossref","unstructured":"Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014;111:628\u201336.","DOI":"10.1038\/bjc.2014.307"},{"key":"109957","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/bjc.2014.307","DOI":"10.1038\/bjc.2014.307"},{"key":"109958","doi-asserted-by":"crossref","unstructured":"Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, et al. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019;186:820\u20138.","DOI":"10.1111\/bjh.15997"},{"key":"109959","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.15997","DOI":"10.1111\/bjh.15997"},{"key":"109960","doi-asserted-by":"crossref","unstructured":"Wynn A, Vacheron A, Zuber J, Solomon SS. Metformin associated with increased survival in type 2 diabetes patients with pancreatic cancer and lymphoma. Am J Med Sci. 2019;358:200\u20133.","DOI":"10.1016\/j.amjms.2019.06.002"},{"key":"109961","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.amjms.2019.06.002","DOI":"10.1016\/j.amjms.2019.06.002"},{"key":"109962","doi-asserted-by":"crossref","unstructured":"Alkhatib Y, Abdel Rahman Z, Kuriakose P. Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. Leuk Lymphoma. 2017;58:1130\u20134.","DOI":"10.1080\/10428194.2016.1239822"},{"key":"109963","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/10428194.2016.1239822","DOI":"10.1080\/10428194.2016.1239822"},{"key":"109964","doi-asserted-by":"crossref","unstructured":"Tseng CH. Metformin use and leukemia risk in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020;11:541090.","DOI":"10.3389\/fendo.2020.541090"},{"key":"109965","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fendo.2020.541090","DOI":"10.3389\/fendo.2020.541090"},{"key":"109966","doi-asserted-by":"crossref","unstructured":"Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.","DOI":"10.1136\/bmj.g7607"},{"key":"109967","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.g7607","DOI":"10.1136\/bmj.g7607"},{"key":"109968","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119:4845\u201350.","DOI":"10.1182\/blood-2011-06-362830"},{"key":"109969","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2011-06-362830","DOI":"10.1182\/blood-2011-06-362830"},{"key":"109970","doi-asserted-by":"crossref","unstructured":"Yan P, Wang Y, Fu T, Liu Y, Zhang ZJ. The association between type 1 and 2 diabetes mellitus and the risk of leukemia: a systematic review and meta-analysis of 18 cohort studies. Endocr J. 2021;68:281\u20139.","DOI":"10.1507\/endocrj.EJ20-0138"},{"key":"109971","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1507\/endocrj.EJ20-0138","DOI":"10.1507\/endocrj.EJ20-0138"},{"key":"109972","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563\u201391.","DOI":"10.2147\/CLEP.S179083"},{"key":"109973","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S179083","DOI":"10.2147\/CLEP.S179083"},{"key":"109974","unstructured":"Pedersen CB, G\u00f8tzsche H, M\u00f8ller JO, Mortensen PB. The Danish Civil Registration system. A cohort of eight million persons. Dan Med Bull. 2006;53:441\u20139."},{"key":"109975","doi-asserted-by":"crossref","unstructured":"Kildemoes HW, Sorensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39:38\u201341.","DOI":"10.1177\/1403494810394717"},{"key":"109976","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1403494810394717","DOI":"10.1177\/1403494810394717"},{"key":"109977","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;2015:449.","DOI":"10.2147\/CLEP.S91125"},{"key":"109978","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S91125","DOI":"10.2147\/CLEP.S91125"},{"key":"109979","doi-asserted-by":"crossref","unstructured":"\u00d8stg\u00e5rd LS, N\u00f8rgaard JM, Raaschou-Jensen KK, Pedersen RS, R\u00f8nnov-Jessen D, Pedersen PT, et al. The Danish national acute leukemia registry. Clin Epidemiol. 2016;8:553\u201360.","DOI":"10.2147\/CLEP.S99460"},{"key":"109980","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S99460","DOI":"10.2147\/CLEP.S99460"},{"key":"109981","doi-asserted-by":"crossref","unstructured":"Rotbain EC, Allmer C, Rostgaard K, Andersen MA, Vainer N, da Cunha-Bang C, et al. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia. Am J Hematol. 2023;98:1236\u201345.","DOI":"10.1002\/ajh.26964"},{"key":"109982","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.26964","DOI":"10.1002\/ajh.26964"},{"key":"109983","doi-asserted-by":"crossref","unstructured":"Kristensen KB, Lund LC, Jensen PB, Broe A, Rotbain E, Damkier P, et al. Development and validation of a Nordic Multimorbidity Index based on hospital diagnoses and filled prescriptions. Clin Epidemiol. 2022;14:567\u201379.","DOI":"10.2147\/CLEP.S353398"},{"key":"109984","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.26964","DOI":"10.1002\/ajh.26964"},{"key":"109985","doi-asserted-by":"crossref","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","DOI":"10.1016\/S0140-6736(18)31041-9"},{"key":"109986","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(18)31041-9","DOI":"10.1016\/S0140-6736(18)31041-9"},{"key":"109987","unstructured":"Lar\u00f8nningen S, Arvidsson G, Bray F, Dahl-Olsen ED, Engholm G, Ervik M, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 9.4 (29.08.2024) [Internet]. Association of the Nordic Cancer Registries. Cancer Registry of Norway. [cited 2025 Apr 03]. Available from: https:\/\/nordcan.iarc.fr\/"},{"key":"109988","doi-asserted-by":"crossref","unstructured":"Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint \u00c5, et al. NORDCAN \u2013 a Nordic tool for cancer information, planning, quality control and research. Acta Oncol (Madr). 2010;49:725\u201336.","DOI":"10.3109\/02841861003782017"},{"key":"109989","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/02841861003782017","DOI":"10.3109\/02841861003782017"},{"key":"109990","doi-asserted-by":"crossref","unstructured":"Xu F, Jin J, Guo J, Xu F, Chen J, Liu Q, et al. The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus. J Cancer Res Clin Oncol. 2024;150:71.","DOI":"10.1007\/s00432-023-05591-4"},{"key":"109991","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00432-023-05591-4","DOI":"10.1007\/s00432-023-05591-4"},{"key":"109992","doi-asserted-by":"crossref","unstructured":"Kyriakou TC, Papageorgis P, Christodoulou MI. Common genetic Aberrations associated with metabolic interferences in human type-2 diabetes and acute myeloid leukemia: a bioinformatics approach. Int J Mol Sci. 2021;22(17):9322.","DOI":"10.3390\/ijms22179322"},{"key":"109993","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms22179322","DOI":"10.3390\/ijms22179322"},{"key":"109994","doi-asserted-by":"crossref","unstructured":"Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129:1320\u201332.","DOI":"10.1182\/blood-2016-08-734798"},{"key":"109995","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2016-08-734798","DOI":"10.1182\/blood-2016-08-734798"},{"key":"109996","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36:868\u201375.","DOI":"10.1016\/j.leukres.2011.12.020"},{"key":"109997","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.leukres.2011.12.020","DOI":"10.1016\/j.leukres.2011.12.020"},{"key":"109998","doi-asserted-by":"crossref","unstructured":"Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, et al. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021;26:393\u20137.","DOI":"10.1080\/16078454.2021.1929692"},{"key":"109999","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/16078454.2021.1929692","DOI":"10.1080\/16078454.2021.1929692"},{"key":"110000","doi-asserted-by":"crossref","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167\u201374.","DOI":"10.1172\/JCI200113505"},{"key":"110001","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1172\/JCI13505","DOI":"10.1172\/JCI13505"},{"key":"110002","doi-asserted-by":"crossref","unstructured":"Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014;508:108\u201312.","DOI":"10.1038\/nature13110"},{"key":"110003","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nature13110","DOI":"10.1038\/nature13110"},{"key":"110004","doi-asserted-by":"crossref","unstructured":"Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159\u201369.","DOI":"10.1038\/nrc3215"},{"key":"110005","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrc3215","DOI":"10.1038\/nrc3215"},{"key":"110006","doi-asserted-by":"crossref","unstructured":"Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, et al. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death Dis. 2018;9:311.","DOI":"10.1038\/s41419-017-0256-4"},{"key":"110007","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41419-017-0256-4","DOI":"10.1038\/s41419-017-0256-4"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42422\/50049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42422\/50049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:05:21Z","timestamp":1756404321000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/42422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":78,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.42422","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}